How do I trace a WWB lot number back to a synthesis date?

I have both a purity figure and a content figure, which is why the discrepancy is visible.

I would like to understand the steps well enough to explain them to someone else.

I have access to a refrigerator with a logger and a freezer without one, which may be relevant.

So: what is the actual procedure, and which steps matter as opposed to being ritual?

The part that matters: if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If testing multiple vials, state how many you tested and why you chose those vials.

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

In practice, the statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

The part that matters: thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

Two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.